1 min read
Add as a preferred source on GoogleTandem Diabetes Care Shares Rise 12% After Tubeless Mobi Clearance
Tandem said the U.S. Food and Drug Administration granted 510(k) clearance for the tubeless system. Shares reached $19.62 at 9:59 a.m. ET.
Tandem Diabetes Care announced Friday that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for a tubeless version of its Mobi insulin-delivery system.
Tandem shares gained $2.11 to $19.62, a 12% increase, at 9:59 a.m. ET (14:59 UTC).
Riza Dagoc
Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.